Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 54.99 kCr |
| Price/Earnings (Trailing) | 65.13 |
| Price/Sales (Trailing) | 8.06 |
| EV/EBITDA | 31.93 |
| Price/Free Cashflow | -1.2 K |
| MarketCap/EBT | 48.54 |
| Enterprise Value | 57.09 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 5.7% |
| Price Change 1M | -3.8% |
| Price Change 6M | 18.5% |
| Price Change 1Y | 69.5% |
| 3Y Cumulative Return | 45.1% |
| 5Y Cumulative Return | 22.1% |
| 7Y Cumulative Return | 47.4% |
Cash Flow & Liquidity |
|---|
| Revenue (TTM) |
| 6.82 kCr |
| Rev. Growth (Yr) | 25.2% |
| Earnings (TTM) | 840.82 Cr |
| Earnings Growth (Yr) | 171% |
Profitability | |
|---|---|
| Operating Margin | 17% |
| EBT Margin | 17% |
| Return on Equity | 17.04% |
| Return on Assets | 8.93% |
| Free Cashflow Yield | -0.08% |
| Cash Flow from Investing (TTM) | -681.72 Cr |
| Cash Flow from Operations (TTM) | 601.65 Cr |
| Cash Flow from Financing (TTM) | 39.28 Cr |
| Cash & Equivalents | 49.77 Cr |
| Free Cash Flow (TTM) | -39.35 Cr |
| Free Cash Flow/Share (TTM) | -0.73 |
Balance Sheet | |
|---|---|
| Total Assets | 9.42 kCr |
| Total Liabilities | 4.48 kCr |
| Shareholder Equity | 4.93 kCr |
| Current Assets | 4.19 kCr |
| Current Liabilities | 3.18 kCr |
| Net PPE | 3.8 kCr |
| Inventory | 2.02 kCr |
| Goodwill | 246.3 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.23 |
| Debt/Equity | 0.44 |
| Interest Coverage | 5.07 |
| Interest/Cashflow Ops | 3.76 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 1.6 |
| Dividend Yield | 0.16% |
| Shares Dilution (1Y) | 0.10% |
| Shares Dilution (3Y) | 0.20% |
Balance Sheet: Strong Balance Sheet.
Technicals: Bullish SharesGuru indicator.
Past Returns: Outperforming stock! In past three years, the stock has provided 45.1% return compared to 13.2% by NIFTY 50.
Size: It is among the top 200 market size companies of india.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Profitability: Recent profitability of 12% is a good sign.
No major cons observed.
Balance Sheet: Strong Balance Sheet.
Technicals: Bullish SharesGuru indicator.
Past Returns: Outperforming stock! In past three years, the stock has provided 45.1% return compared to 13.2% by NIFTY 50.
Size: It is among the top 200 market size companies of india.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Profitability: Recent profitability of 12% is a good sign.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.16% |
| Dividend/Share (TTM) | 1.6 |
| Shares Dilution (1Y) | 0.10% |
| Earnings/Share (TTM) | 15.64 |
Financial Health | |
|---|---|
| Current Ratio | 1.32 |
| Debt/Equity | 0.44 |
Technical Indicators | |
|---|---|
| RSI (14d) | 55.18 |
| RSI (5d) | 62.71 |
| RSI (21d) | 46.29 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Summary of Laurus Labs's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Laurus Labs management provided an optimistic outlook during the Q3 FY'26 earnings call, highlighting their robust financial performance and strategic advancements across key business segments. Key financial metrics included revenues of Rs. 1,778 crores for Q3, with a gross margin maintained at around 60% and EBITDA margin at 27%. Management expects to achieve sustained operational growth for the fiscal year.
Key forward-looking points include:
Looking ahead, Laurus Labs is committed to enhancing operational efficiencies and navigating challenges in the CDMO space while leveraging its investments to meet growing demand.
Understand Laurus Labs ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava) | 22.99% |
| NEW WORLD FUND INC | 5.27% |
| ANUKAR PROJECTS PRIVATE LIMITED | 3.24% |
| MIRAE ASSET NIFTY SMALLCAP 250 ETF | 3.05% |
| CHUNDURU VENKATA LAKSHMANA RAO | 2.65% |
| BARCLAYS WEALTH TRUSTEES INDIA PRIVATE LIMITED | 1.61% |
Detailed comparison of Laurus Labs against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.11 LCr | 58.94 kCr | -0.80% | +1.20% | 37.69 | 6.98 | - | - |
| DIVISLAB | Divi's Lab | 1.64 LCr |
Comprehensive comparison against sector averages
LAURUSLABS metrics compared to Pharmaceuticals
| Category | LAURUSLABS | Pharmaceuticals |
|---|---|---|
| PE | 64.81 | 34.10 |
| PS | 8.02 | 4.71 |
| Growth | 28.5 % | 10 % |
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
LAURUSLABS vs Pharmaceuticals (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Here are the major questions and their detailed answers from the Q&A section of the earnings transcript for Laurus Labs Limited's Q3 FY'26 results:
Question: "Could you break down ARV sales into formulations and API?" Answer: In the 9 months, our ARV formulation sales stood at Rs. 865 crores, while API sales were Rs. 1,259 crores. For Quarter 3, total ARV revenues tallied at Rs. 744 crores.
Question: "What is your CAPEX outlook for peptides and ADCs in the coming years?" Answer: We have allocated $25 million for our GMP facility under construction for ADCs, but we don't expect significant revenues for the next two years. For peptide commercial manufacturing facilities, we anticipate qualification this year, with more details to follow.
Question: "What are your overall CAPEX expectations for FY "˜27?" Answer: We expect this year's CAPEX to reach around Rs. 1,000 crores, continuing into FY '27 at a similar or slightly higher level.
Question: "What is the expected CDMO revenue growth for FY '27?" Answer: For FY "˜27, while concrete numbers are not provided, we expect healthy growth driven by commercial supplies from late-stage programs, indicating sustained demand.
Question: "What creates the improvement in gross margins noticed?" Answer: The margin improvements resulted from a favorable product mix and efficiency gains, and we anticipate maintaining gross margins around 60% in the upcoming quarter.
Question: "What is the competitive advantage Laurus has in the CDMO space?" Answer: Our preparedness for complex chemistry and scale, supported by significant investments over the past years, positions us strongly compared to competitors, especially for high-energy and flow chemistry processes.
Question: "How do we interpret the strong operating cash flow seen?" Answer: The robust cash flow conversion results from various customer advances. We recognize that while the cash flow metrics show improvement, comparisons from quarter-to-quarter require understanding of the cyclic nature of customer payments.
Question: "Can you explain the new MoU with LORDIN regarding OLED materials?" Answer: The MoU with LORDIN aims to explore opportunities in OLED materials, which are chemically synthesized small molecules. However, we do not expect significant revenues from this initiative in the immediate future.
Question: "How do you see the ARV segment developing going forward?" Answer: We previously guided ARV revenue stabilization around Rs. 2,500 crores, but currently, we expect around Rs. 2,600 crores due to expanded API capacity now serving the increased market demand.
Question: "What will be the impact of new capacities and orders on future segmental revenue?"
Answer: We anticipate sustained revenue growth from our generics and CDMO segments, driven by new capacities coming online and existing partnerships across various sectors helping enhance our order book.
All answers are within 500 characters and contain key details and numbers.
| AKASH BHANSHALI | 1.32% |
| M/s. Leven Holdings (Represented by its Managing Partner, Mr. Venkata Ravi Kumar Vantaram) | 1.15% |
| SBI LARGE & MIDCAP FUND | 1.12% |
| KOTAK FUNDS - INDIA MIDCAP FUND | 1.1% |
| SATYANARAYANA CHAVA | 0.29% |
| VENKATA RAVI KUMAR VANTARAM | 0.19% |
| KRISHNAVENI VASIREDDI | 0.04% |
| HYMAVATHI VANTARAM | 0.04% |
| RAMA SURYADEVARA | 0.03% |
| NARASIMHA RAO SURYADEVARA | 0.03% |
| SEKHAR BABU CHUNDURU | 0.02% |
| KAMALA KOMMANA | 0.02% |
| NAGAMANI THOKALA | 0.02% |
| CHAVA NARASIMHA RAO | 0.02% |
Distribution across major stakeholders
Distribution across major institutional holders
| 10.75 kCr |
| -3.90% |
| +3.60% |
| 66.24 |
| 15.27 |
| - |
| - |
| CIPLA | Cipla | 1.07 LCr | 29.37 kCr | -8.20% | -8.30% | 23.61 | 3.65 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.06 LCr | 36.09 kCr | +7.00% | +4.90% | 19.07 | 2.95 | - | - |
| AUROPHARMA | Aurobindo Pharma | 67.25 kCr | 33.73 kCr | -0.80% | +1.20% | 19.29 | 1.99 | - | - |
| 7.5% |
| 1,457 |
| 1,356 |
| 1,467 |
| 1,294 |
| 1,205 |
| 1,179 |
| Profit Before exceptional items and Tax | 46.2% | 327 | 224 | 312 | 131 | 23 | 18 |
| Total profit before tax | 46.2% | 327 | 224 | 312 | 131 | 23 | 18 |
| Current tax | 18.6% | 71 | 60 | 80 | 35 | 23 | 18 |
| Deferred tax | -53.3% | 1.99 | 3.12 | -1.87 | 5.1 | -18.09 | -12.16 |
| Total tax | 16.1% | 73 | 63 | 78 | 40 | 5.09 | 6.25 |
| Total profit (loss) for period | 55.9% | 252 | 162 | 233 | 93 | 20 | 13 |
| Other comp. income net of taxes | -52% | -1.6 | -0.71 | -2.07 | -1.47 | -0.42 | 0.31 |
| Total Comprehensive Income | 55.6% | 250 | 161 | 231 | 91 | 20 | 13 |
| Earnings Per Share, Basic | 81.7% | 4.67 | 3.02 | 4.34 | 1.71 | 0.37 | 0.23 |
| Earnings Per Share, Diluted | 80.7% | 4.65 | 3.02 | 4.33 | 1.71 | 0.37 | 0.23 |
| 10.3% |
| 609 |
| 552 |
| 497 |
| 445 |
| 402 |
| 324 |
| Finance costs | 20.7% | 182 | 151 | 146 | 96 | 66 | 88 |
| Depreciation and Amortization | 4.1% | 359 | 345 | 301 | 235 | 197 | 184 |
| Other expenses | 8.7% | 1,201 | 1,105 | 1,083 | 768 | 682 | 501 |
| Total Expenses | 5.6% | 4,814 | 4,558 | 4,738 | 3,753 | 3,521 | 2,499 |
| Profit Before exceptional items and Tax | 67.7% | 504 | 301 | 1,051 | 975 | 1,275 | 304 |
| Total profit before tax | 67.7% | 504 | 301 | 1,051 | 975 | 1,275 | 304 |
| Current tax | 75.9% | 154 | 88 | 271 | 231 | 335 | 53 |
| Deferred tax | -181.3% | -30.42 | -10.17 | 20 | -6.1 | -16.46 | -15.57 |
| Total tax | 58.4% | 123 | 78 | 291 | 225 | 319 | 37 |
| Total profit (loss) for period | 70% | 380 | 224 | 760 | 750 | 956 | 267 |
| Other comp. income net of taxes | 0% | -0.76 | -0.76 | 0.79 | 0.8 | 5.12 | -9.62 |
| Total Comprehensive Income | 70.7% | 380 | 223 | 761 | 751 | 961 | 257 |
| Earnings Per Share, Basic | 92.4% | 7.06 | 4.15 | 14.14 | 13.97 | 17.85 | 56 |
| Earnings Per Share, Diluted | 92.1% | 7.05 | 4.15 | 14.09 | 13.91 | 17.77 | 56 |
| - |
| 0 |
| 0 |
| 112 |
| 116 |
| 93 |
| 91 |
| Non-current investments | 9.1% | 807 | 740 | 635 | 635 | 432 | 384 |
| Loans, non-current | 0% | 466 | 466 | 318 | 226 | 191 | 64 |
| Total non-current financial assets | -3.3% | 1,313 | 1,358 | 997 | 905 | 668 | 495 |
| Total non-current assets | 4.7% | 4,795 | 4,580 | 4,224 | 4,150 | 3,939 | 3,787 |
| Total assets | 1.2% | 8,692 | 8,587 | 8,088 | 7,667 | 7,322 | 6,958 |
| Borrowings, non-current | -16.7% | 345 | 414 | 393 | 491 | 453 | 565 |
| Total non-current financial liabilities | -16.7% | 384 | 461 | 444 | 544 | 484 | 594 |
| Provisions, non-current | 5.2% | 102 | 97 | 92 | 88 | 89 | 79 |
| Total non-current liabilities | 12.7% | 970 | 861 | 733 | 725 | 680 | 795 |
| Borrowings, current | -25.2% | 1,429 | 1,910 | 1,890 | 1,559 | 1,319 | 1,116 |
| Total current financial liabilities | -13.7% | 2,626 | 3,041 | 2,985 | 2,602 | 2,329 | 1,931 |
| Provisions, current | 3.7% | 29 | 28 | 26 | 24 | 22 | 19 |
| Current tax liabilities | 103.8% | 107 | 53 | 33 | 34 | 17 | 44 |
| Total current liabilities | -11.3% | 2,804 | 3,162 | 3,085 | 2,736 | 2,588 | 2,106 |
| Total liabilities | -6.2% | 3,774 | 4,023 | 3,818 | 3,460 | 3,269 | 2,901 |
| Equity share capital | 0% | 108 | 108 | 108 | 108 | 108 | 108 |
| Total equity | 7.8% | 4,918 | 4,564 | 4,270 | 4,207 | 4,053 | 4,057 |
| Total equity and liabilities | 1.2% | 8,692 | 8,587 | 8,088 | 7,667 | 7,322 | 6,958 |
| 37.1% |
| 134 |
| 98 |
| 268 |
| 166 |
| - |
| - |
| Other inflows (outflows) of cash | 1048% | 46 | 4.92 | 1.08 | 0 | - | - |
| Net Cashflows From Operating Activities | -18.1% | 540 | 659 | 882 | 823 | - | - |
| Cashflows used in obtaining control of subsidiaries | -100.4% | 0 | 251 | 22 | 43 | - | - |
| Proceeds from sales of PPE | 17718.2% | 99 | 1.55 | 1.23 | 0.06 | - | - |
| Purchase of property, plant and equipment | 3.8% | 381 | 367 | 742 | 761 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | -18.3% | 99 | 121 | 66 | 0 | - | - |
| Interest received | 61.9% | 35 | 22 | 10 | 12 | - | - |
| Other inflows (outflows) of cash | - | 0.01 | 0 | -0.05 | -0.23 | - | - |
| Net Cashflows From Investing Activities | 21.8% | -591.65 | -756.74 | -735.27 | -836.61 | - | - |
| Proceeds from exercise of stock options | 476.9% | 10 | 2.56 | 7.44 | 4.31 | - | - |
| Proceeds from borrowings | -5.1% | 525 | 553 | 270 | 377 | - | - |
| Repayments of borrowings | 36.5% | 244 | 179 | 226 | 155 | - | - |
| Payments of lease liabilities | 71.6% | 12 | 7.41 | 5.79 | 45 | - | - |
| Dividends paid | -50.6% | 43 | 86 | 107 | 86 | - | - |
| Interest paid | 23.2% | 176 | 143 | 123 | 80 | - | - |
| Net Cashflows from Financing Activities | -58% | 59 | 139 | -185.19 | 15 | - | - |
| Net change in cash and cash eq. | -83.2% | 7.73 | 41 | -38.91 | 1.55 | - | - |